ESMO Young Oncologist Journal Club

The ESMO Young Oncologists Committee is proud to host the Young Oncologist Journal Club. On a regular basis (1-3 times a month), a committee member – or a specially invited young oncologists – provides you with an appraisal of an important clinical and/or translational article published in a major journal. The appraisers add their comments analysing the clinical relevance of the article and possible considerations.

Get involved by reading the review, share your thoughts and raise questions for discussion by logging in and commenting on the article. Commenting is reserved to ESMO Members only. We look forward to your input!

Submit an article


Topic Title Author
Breast cancer Pathologic Complete Response after Neoadjuvant Chemotherapy - the “pCRness” of breast cancer subtypes Evandro de Azambuja
Intratumour Heterogeneity: Does the strength of a tree lie in its trunk or in its branches? Leticia De Mattos-Arruda
Palliative and supportive care Patient Selection for Oncology Phase I Trials: a multi-institutional study of prognostic factors Jesus Corral
Sarcomas Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients with Advanced Bone and Soft Tissue Sarcomas Jörn Rüssel, MD
Gastrointestinal cancers Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition Through Feedback Activation of EGFR Matthias Preusser
Breast cancer FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer Tamer Refaat
Gastrointestinal cancers Adjuvant Therapy for Completely Resected Gastric Cancer with D2 LN Dissection Konstantinos Kamposioras
Head and neck cancers Nasopharyngeal Carcinoma – a rare but potentially curable disease Michalis V. Karamouzis
Gynaecologic malignancies Bevacizumab in the Primary Treatment of Advanced Ovarian Cancer Susana Banerjee
Breast cancer Overcoming Endocrine Resistance in Advanced Breast Cancer by Inhibiting the mTOR Pathway Valentina Guarneri
Anticancer agents & Biologic therapy Prospective Molecular Marker Analyses of EGFR and KRAS from a Randomised Placebo-Controlled Study of Erlotinib Maintenance therapy in Advanced Non-Small-Cell-Lung Cancer Marina Chiara Garassino; Sheila Piva
Palliative and supportive care ASCO Practice Guideline on Antiemesis, update Nov. 2011 Karin Jordan
Lung and other thoracic tumours Chemotherapy and Vascular Disrupting Agents in advanced NSCLC: still looking for an ATTRACT-1ve partner Raffaele Califano
Central nervous system malignancies Bevacizumab-Induced Tumour Calcifications as a Surrogate Marker of Outcome in Patients with Glioblastoma Matthias Preusser
Lung and other thoracic tumours Randomised Phase II Study of Erlotinib plus Tivantinib versus Erlotinib plus Placebo in Pretreated NSCLC Patients: have we found a KRAS targeting agent? Giulio Metro